Good morning. Here is Matt Lowdon‘s medtech and biotech deal headlines for last week. Some interesting moves, including surgical tools, VC fund raising records, neuromodulation, AI buying up bio, and more. Let me know if I missed anything.
➡️ WHOOP raises $575M series G, Abbott comes on board amid hiring spree
➡️ AI powerhouse Anthropic is continuing its push into the healthcare arena with the acquisition of previously stealth AI biotech startup Coefficient Bio in a $400 million stock deal
➡️ Buoyed by $100M series A, Stipple Bio debuts to advance lead oncology asset into clinic
➡️ Months after $100M series A, Syneron Bio closes $150M round to support peptide platform
➡️ Eli Lilly and Company has agreed to acquire UK-based Centessa Pharmaceuticals in a deal worth up to $7.8 billion, giving the pharma giant a high-profile entry into one of biotech’s most closely watched neuroscience fields: orexin biology
➡️ ANEUVO, a Los Angeles-based medical technology company advancing non-invasive neuromodulation for people living with spinal cord injury, announced the closing of a Series C funding round of $22M
➡️ Colorado drugmaker Ambrosia Biosciences Inc. has landed $100 million to pursue an oral obesity drug it’s hoping can compete with a recently approved version of Wegovy.
➡️ Amani Therapeutics Closes $25 Million Series A to Advance AM-01, a Potential Best-in-Class Therapy for Serious Neuropsychiatric Disorders
➡️ US investment firm Blackstone has closed its sixth life sciences fund at $6.3 billion, marking the largest private vehicle ever raised for the sector.
➡️ KatoMed, a UC San Diego MedTech Accelerator company, shines with their surgical navigation tool after a recent investment from Kyocera Ventures.